/MBX

MBX Biosciences Inc

MBX

$59.02USD↓-3.15%-1.92 today

MARKET CAP

2.8B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$58 – $62

52W RANGE

$10

$73

AI Summary

Stalk

Sell NowMedium

MBX is in a Stage 4 decline following support failure through key EMAs, establishing a medium-term bearish bias. Short-term price remains below declining EMAs with no exhaustion pattern, aligning with a momentum strategy that favors selling into rallies around the broken support cluster near the 9/20/50 EMA zone. The long-term uptrend stays intact above the rising 200-day SMA.

↑Promising Phase 3 trial for canvuparatide in Q3 2026 after strong one-year data.
↑$418.6M in cash and securities funds operations into 2029, reducing near-term dilution.
↓Q2 2026 net loss of $37.1M ($0.78/share) vs $19.4M prior year, missing consensus by $0.10.

Full analysis →

Buying

4

institutions

Selling

6

institutions

New Positions

3

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	3.32 M	183.47 M	+382.27 K	+109.0%	0.00%
WP Woodline Partners LP Q2 2026	SELL	900.09 K	49.69 M	+-900.03 K	-7.5%	0.15%
MM Millennium Management LLC Q2 2026	SELL	226.15 K	12.48 M	+-338.26 K	-25.9%	0.00%
JC Jpmorgan Chase & Co Q2 2026	SELL	139.61 K	7.52 M	+-7.45 K	+89.9%	0.00%
MC Moore Capital Management, LP Q2 2026	BUYNEW	64.89 K	3.58 M	+64.89 K	+0.0%	0.05%
CA Citadel Advisors LLC Q2 2026	SELL	26.20 K	1.45 M	+-941.83 K	-95.0%	0.00%
AC Aqr Capital Management LLC Q2 2026	SELL	22.59 K	1.25 M	+-4.80 K	+52.5%	0.00%
JH Janus Henderson Group Plc Q1 2026	BUYNEW	20.60 K	616.35 K	+20.60 K	+0.0%	0.00%
BH Brevan Howard Capital Management LP Q2 2026	BUYNEW	8.60 K	474.83 K	+8.60 K	+0.0%	0.00%
RC Rockefeller Capital Management L.P. Q2 2026	SELL	224.00	12.37 K	+-3.00 K	-87.2%	0.00%